|Day's Range||53.69 - 54.58|
|52 Week Range||46.01 - 77.12|
|PE Ratio (TTM)||18.89|
|Dividend & Yield||1.56 (2.90%)|
|1y Target Est||N/A|
Bristol-Myers Squibb Company (BMY) announced that the FDA has accepted and granted a priority review designation to the supplemental Biologics License Application for the label expansion of Opdivo to patients with hepatocellular carcinoma (HCC).
Biotech M&A deals are often driven by the buyer's interest in the lead asset in the biotech's portfolio. In order to capture the full value, spin-outs of the secondary assets following an acquisition can be solution. Several recent examples hare explored.
Combined sales for Januvia and Janumet were ~$1.3 billion for 1Q17, a ~5.0% fall from $1.4 billion in 1Q16.